Saltar al contenido
Merck
Todas las fotos(1)

Documentos

SML1935

Sigma-Aldrich

Nimorazole

≥98% (HPLC)

Sinónimos:

4-(2-(5-Nitro-1H-imidazol-1-yl)ethyl)morpholine, K 1900, K-1900, K1900, NSC 107524, NSC-107524, NSC107524

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C9H14N4O3
Número de CAS:
6506-37-2
Peso molecular:
226.23
EC Number:
229-394-4
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 30 mg/mL, clear

storage temp.

2-8°C

InChI

1S/C9H14N4O3/c14-13(15)9-7-10-8-12(9)2-1-11-3-5-16-6-4-11/h7-8H,1-6H2

InChI key

MDJFHRLTPRPZLY-UHFFFAOYSA-N

Biochem/physiol Actions

Nimorazole is a nitroimidazole-based hypoxic cell-radiation sensitizer with less toxicity than etanidazole or misonidazole. Under low oxygen (hypoxic) condition, reductive activation of its 5-nitroimidazole moiety leads to enhanced adduct formation with reduced glutathione, which form the basis of cancer/tumour-selective radiation sensitization. Nimorazole is also a known anti-infective agent against trichomoniasis, an infectious disease caused by the protozoan parasite Trichomonas vaginalis.

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Muta. 1B - Repr. 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Thomas R Wittenborn et al.
Acta oncologica (Stockholm, Sweden), 54(9), 1385-1392 (2015-09-04)
Hypoxia is a characteristic feature of solid tumours that significantly reduces the efficacy of conventional radiation therapy. In this study we investigated the role of hypoxia in a stereotactic radiation schedule by using a variety of hypoxic modifiers in a
Thomas M Ashton et al.
Nature communications, 7, 12308-12308 (2016-07-28)
Tumour hypoxia renders cancer cells resistant to cancer therapy, resulting in markedly worse clinical outcomes. To find clinical candidate compounds that reduce hypoxia in tumours, we conduct a high-throughput screen for oxygen consumption rate (OCR) reduction and identify a number
Radiotherapy quality assurance of the IAEA-HypoX trial of the accelerated radiotherapy in the treatment of head and neck squamous cell carcinoma with or without the hypoxic radiosensitizer nimorazole.
Mohamed A Hassan Metwally et al.
Acta oncologica (Stockholm, Sweden), 54(9), 1673-1677 (2015-09-24)

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico